Biogened Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Biogened has been growing earnings at an average annual rate of 31.8%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 19.2% per year. Biogened's return on equity is 13.7%, and it has net margins of 5.1%.
Belangrijke informatie
31.8%
Groei van de winst
32.5%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 29.4% |
Inkomstengroei | 19.2% |
Rendement op eigen vermogen | 13.7% |
Nettomarge | 5.1% |
Volgende winstupdate | 14 Nov 2024 |
Recente prestatie-updates uit het verleden
Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)
Aug 22Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations
Feb 21Recent updates
A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb
Aug 28Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)
Aug 22Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding
May 23Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden
May 09Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations
Feb 21Is Biogened (WSE:BGD) A Risky Investment?
Feb 01Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump
Feb 01We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt
Jun 30Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly
Oct 08Is Biogened (WSE:BGD) A Risky Investment?
Jun 29Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?
Mar 25These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well
Dec 09Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet
Jul 29Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly
Apr 30Is Biogened (WSE:BGD) A Risky Investment?
Jan 24Opbrengsten en kosten
Hoe Biogened geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 106 | 5 | 61 | 0 |
31 Mar 24 | 100 | 4 | 58 | 0 |
31 Dec 23 | 96 | 5 | 55 | 0 |
30 Sep 23 | 92 | 4 | 47 | 0 |
30 Jun 23 | 90 | 4 | 46 | 0 |
31 Mar 23 | 85 | 4 | 45 | 0 |
31 Dec 22 | 80 | 3 | 42 | 0 |
30 Sep 22 | 77 | 4 | 41 | 0 |
30 Jun 22 | 72 | 4 | 36 | 0 |
31 Mar 22 | 70 | 3 | 36 | 0 |
31 Dec 21 | 65 | 2 | 35 | 0 |
30 Sep 21 | 57 | 2 | 33 | 0 |
30 Jun 21 | 54 | 2 | 33 | 0 |
31 Mar 21 | 50 | 1 | 30 | 0 |
31 Dec 20 | 48 | 1 | 30 | 0 |
30 Sep 20 | 49 | 2 | 29 | 0 |
30 Jun 20 | 48 | 1 | 29 | 0 |
31 Mar 20 | 48 | 1 | 29 | 0 |
31 Dec 19 | 47 | 1 | 28 | 0 |
30 Sep 19 | 45 | 1 | 28 | 0 |
30 Jun 19 | 44 | 1 | 27 | 0 |
31 Mar 19 | 41 | 1 | 26 | 0 |
31 Dec 18 | 40 | 1 | 26 | 0 |
30 Sep 18 | 39 | 1 | 24 | 0 |
30 Jun 18 | 39 | 1 | 24 | 0 |
31 Mar 18 | 36 | 1 | 22 | 0 |
31 Dec 17 | 34 | 1 | 21 | 0 |
30 Sep 17 | 30 | 1 | 19 | 0 |
30 Jun 17 | 31 | 1 | 20 | 0 |
31 Mar 17 | 29 | 1 | 19 | 0 |
31 Dec 16 | 29 | 1 | 19 | 0 |
30 Sep 16 | 32 | 2 | 21 | 0 |
30 Jun 16 | 31 | 2 | 20 | 0 |
31 Mar 16 | 31 | 3 | 19 | 0 |
31 Dec 15 | 30 | 3 | 18 | 0 |
30 Sep 15 | 30 | 2 | 18 | 0 |
30 Jun 15 | 26 | 1 | 15 | 0 |
31 Mar 15 | 24 | 1 | 14 | 0 |
31 Dec 14 | 23 | 1 | 13 | 0 |
30 Sep 14 | 20 | 1 | 12 | 0 |
30 Jun 14 | 21 | 1 | 12 | 0 |
31 Mar 14 | 22 | 1 | 13 | 0 |
31 Dec 13 | 22 | 2 | 12 | 0 |
Kwaliteitswinsten: BGD has high quality earnings.
Groeiende winstmarge: BGD's current net profit margins (5.1%) are higher than last year (3.9%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: BGD's earnings have grown significantly by 31.8% per year over the past 5 years.
Versnelling van de groei: BGD's earnings growth over the past year (53%) exceeds its 5-year average (31.8% per year).
Winst versus industrie: BGD earnings growth over the past year (53%) exceeded the Pharmaceuticals industry 4.5%.
Rendement op eigen vermogen
Hoge ROE: BGD's Return on Equity (13.7%) is considered low.